Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy

Bethany Lockwood, MD, Areej El-Jawahri, MD, Alison R. Walker, MD, Deborah Russell, FNP-BC,ACHPN, Jillian Gustin, MD, Sarah Ehrman, MD, Seuli Bose-Brill, MD, Maryam Lustberg, MD, Bhavana Bhatnagar, DO

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-140589

Published: 2020

Journal Articles

Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial

Blood (2019) 134 (Supplement_1): 175.

https://doi.org/10.1182/blood-2019-130201

Published: 2019

Journal Articles

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Bhavana Bhatnagar, DO, Shelley Orwick, BS, Nyla A. Heerema, PhD, Alison R. Walker, MD, Alice S. Mims, MD, James S. Blachly, MD, Karilyn Larkin, MD, Nicole Grieselhuber, MD PhD, Gregory K. Behbehani, MD PhD, Apollinaire Ngankeu, Charles Thomas Gregory, BS, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1329.

https://doi.org/10.1182/blood-2019-130856

Published: 2019

Journal Articles

Decitabine Super-Responders: Challenging the Dogma of Long-Term Remission for Acute Myeloid Leukemia

Joseph Maakaron, MD, Gabriel N. Mannis, MD, Alison R. Walker, MD, Alice S. Mims, MD

Blood (2018) 132 (Supplement 1): 5190.

https://doi.org/10.1182/blood-2018-99-119916

Published: 2018

Journal Articles

Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

Blood (2018) 132 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2018-99-114100

Published: 2018

Journal Articles

The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia

Nicole R. Grieselhuber, MD PhD, Shaneice R. Mitchell, BS, Shelley Orwick, BS, Bonnie K. Harrington, DVM, Virginia M. Goettl, DVM, PhD, Alison R. Walker, MD MPH, Bhavana Bhatnagar, DO, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Sumithra Vasu, MBBS, William Blum, MD, James S. Blachly, MD, David M. Lucas, PhD, Ramiro Garzon, MD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3941.

https://doi.org/10.1182/blood.V128.22.3941.3941

Published: 2016

Journal Articles

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

Swagata Goswami, MS, Rajeswaran Mani, DVM PhD, Chi-Ling Chiang, MS, Frank W Frissora, M.S., Xiaokui Mo, PhD MAS, Zhiliang Xie, Donna Bucci, Amber Gordon, MLS, David M. Lucas, PhD, William Blum, MD, Alison R. Walker, MD MPH, Alice S. Mims, MD MSCR, Rebecca B Klisovic, MD, Ching-Shih Chen, PhD, Robert J Lee, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Sumithira Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 2748.

https://doi.org/10.1182/blood.V128.22.2748.2748

Published: 2016

Journal Articles

Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia

Alison R. Walker, MD MPH, Bhavana Bhatnagar, DO, A. Mario Q. Marcondes, MD, Julie DiPaolo, PhD, Sumithra Vasu, MBBS, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Katherine J. Walsh, MD, Renee Canning, RN, Gregory K. Behbehani, MD PhD, Ramiro Garzon, MD, James S. Blachly, MD, Amy J. Johnson, PhD, Esteban Abella-Dominicis, John C. Byrd, MD, William Blum, MD

Blood (2016) 128 (22): 2831.

https://doi.org/10.1182/blood.V128.22.2831.2831

Published: 2016

Journal Articles

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Rajeswaran Mani, DVM PhD, Swagata Goswami, MS, Bhavani Gopalakrishnan, Rahul Ramaswamy, Ronni Wasmuth, Minh Tran, Xiaokui Mo, PhD MAS, Amber Gordon, MLS, Donna Bucci, David Lucas, PhD, Christopher L. Brooks, PhD, Alison R. Walker, MD MPH, William Blum, MD, John C. Byrd, MD, Gerard Lozanski, MD, Sumithra Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 580.

https://doi.org/10.1182/blood.V128.22.580.580

Published: 2016

Journal Articles

Performance of Quick Sepsis-Related Organ Failure Assessment (qSOFA) in Predicting Adverse Outcomes in Acute Leukemia Patients Receiving Induction Chemotherapy

John Vaughn, MD, David Kline, PhD, Nathan Denlinger, DO, Leslie Andritsos, MD, Alison R. Walker, MD MPH

Blood (2016) 128 (22): 2413.

https://doi.org/10.1182/blood.V128.22.2413.2413

Published: 2016

Journal Articles

A Novel Regimen for Acute Myeloid Leukemia with MLL Partial Tandem Duplication: Results of a Phase 1 Study NCI 8485

Alice S. Mims, MD MSCR, Rebecca B Klisovic, MD, Ramiro Garzon, MD, Alison R. Walker, MD MPH, Steven M. Devine, MD, Katherine J. Walsh, MD, Sumithira Vasu, MBBS, Susan P. Whitman, PhD, Guido Marcucci, MD, Nyla A. Heerema, PhD, Michael A. Caligiuri, MD, Clara D. Bloomfield, MD, John C. Byrd, MD, Richard Piekarz, PhD MD, Michael R. Grever, MD, William Blum, MD

Blood (2016) 128 (22): 900.

https://doi.org/10.1182/blood.V128.22.900.900

Published: 2016

Journal Articles

A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

Bhavana Bhatnagar, DO, Rebecca B. Klisovic, MD, Alison R. Walker, MD MPH, Sumithra Vasu, MBBS, Alice S. Mims, MD MSCR, Katherine J. Walsh, MD, Gregory K. Behbehani, MD PhD, James S. Blachly, MD, Molly Vittorio, Qiuhong Zhao, Amy S. Ruppert, MAS, Shelley Orwick, BS, Parvathi Ranganathan, PhD, John C. Byrd, MD, William Blum, MD, Ramiro Garzon, MD

Blood (2016) 128 (22): 1651.

https://doi.org/10.1182/blood.V128.22.1651.1651

Published: 2016

Journal Articles

A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia

Daniel J. DeAngelo, Alison R. Walker, MD, Richard F. Schlenk, MD, Jorge Sierra, Bruno C. Medeiros, MD, Enrique M. Ocio, Christoph Röllig, Stephen A. Strickland, MD, Felicitas Thol, MD, Sue-zette Valera, Antje Wegener, Tuli De, Song Mu, PhD, Florence Binlich, Robert K. Stuart, MD

Blood (2015) 126 (23): 2553.

https://doi.org/10.1182/blood.V126.23.2553.2553

Published: 2015

Journal Articles

In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease

Shaneice Mitchell, BS, Shelley Orwick, BS, Matthew Cannon, BS, Virginia M. Goettl, DVM , PhD, Taylor D. LaFollette, Erkan Baloglu, PhD, William Senapedis, PhD, Alison R. Walker, MD, Bhavana Bhatnagar, Alice S. Mims, MD, Rebecca B. Klisovic, MD, Sumithira Vasu, MBBS, William Blum, MD, David M. Lucas, PhD, James S. Blachly, MD, Ramiro Garzon, MD, Clara D. Bloomfield, MD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2015) 126 (23): 2471.

https://doi.org/10.1182/blood.V126.23.2471.2471

Published: 2015

Journal Articles

A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b

Hongyan Wang, PhD, Ramasamy Santhanam, Ph.D, Zhiliang Xie, MD, Xiaomeng Huang, Ming Chiu, Mitch A. Phelps, PhD, Alison R Walker, MD, Michael A. Caligiuri, MD, Ramiro Garzon, MD, James Lee, PhD, Natarajan Muthusamy, DVM, Ph.D, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2013) 122 (21): 3933.

https://doi.org/10.1182/blood.V122.21.3933.3933

Published: 2013

Journal Articles

Phase I Study Of The Combination Of Midostaurin, Bortezomib and Chemotherapy In Relapsed/Refractory Acute Myeloid Leukemia (AML): Targeting Aberrant Tyrosine Kinase Activity

Alison R Walker, MD, Hongyan Wang, PhD, Rebecca Klisovic, MD, Katherine Walsh, MD, Sumithira Vasu, MBBS, Ramiro Garzon, MD, Steven M. Devine, MD, Amy Drake, William Blum, MD, Guido Marcucci, MD

Blood (2013) 122 (21): 3966.

https://doi.org/10.1182/blood.V122.21.3966.3966

Published: 2013

Journal Articles

Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML)

Alison R. Walker, MD, Klaus H. Metzeler, MD, Susan Geyer, PhD, Heiko Becker, MD, Sebastian Schwind, MD, Susan P. Whitman, PhD, John Curfman, Yue-Zhong Wu, MS, Danilo Perrotti, MD, Ph.D, Rebecca B. Klisovic, MD, Ramiro Garzon, MD, William Blum, MD, Guido Marcucci, MD

Blood (2011) 118 (21): 944.

https://doi.org/10.1182/blood.V118.21.944.944

Published: 2011

NARROW

Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy

Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial

NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy

Decitabine Super-Responders: Challenging the Dogma of Long-Term Remission for Acute Myeloid Leukemia

Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation

The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Performance of Quick Sepsis-Related Organ Failure Assessment (qSOFA) in Predicting Adverse Outcomes in Acute Leukemia Patients Receiving Induction Chemotherapy

A Novel Regimen for Acute Myeloid Leukemia with MLL Partial Tandem Duplication: Results of a Phase 1 Study NCI 8485

A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia

In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease

A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b

Phase I Study Of The Combination Of Midostaurin, Bortezomib and Chemotherapy In Relapsed/Refractory Acute Myeloid Leukemia (AML): Targeting Aberrant Tyrosine Kinase Activity

Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only